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Abstract Introduction The classification of malignant
sweat gland lesions is complex. Traditionally, cutaneous
sweat gland tumors have been classified by either eccrine
or apocrine features. Methods A case report of a 33-year-
old Hispanic man with a left scalp mass diagnosed as a
malignancy of adnexal origin preoperatively is discussed.
After presentation at our multidisciplinary tumor board,
excision with ipsilateral neck dissection was undertaken.
Results Final pathology revealed an apocrine hidradeno-
carcinoma. The classification and behavior of this entity
are discussed in this report. Conclusion Apocrine hidrad-
enocarcinoma can be viewed as an aggressive malignant
lesion of cutaneous sweat glands on a spectrum that
involves both eccrine and apoeccrine lesions.
Keywords Apocrine  Eccrine  Hidradenocarcinoma 
Sweat gland  Scalp  Head  Neck
Introduction
The skin is the largest organ of the body and is composed
of two principal layers, the epidermis and dermis. Arising
out of the ectoderm and eventually existing within the
dermis are specialized structures referred to as skin
appendages. Skin appendages are subdivided into three
categories: the pilosebaceous unit, the eccrine cutaneous
sweat gland, and the apocrine cutaneous sweat gland.
Eccrine sweat glands are found throughout the body but
especially on the palms and soles. Apocrine sweat glands
tend to be limited to the face, axilla, and anogenital areas
[1].
Skin adnexal tumors can arise from any of these skin
appendages. For example, pilosebaceous units are thought
to give rise to trichilemmal carcinoma and sebaceous car-
cinoma. Some examples of tumors of supposed eccrine
origin include porocarcinoma and hidradenocarcinoma,
though apocrine differentiation of the former has been seen
as well. Apocrine carcinoma and syringocystadenocarci-
noma are thought to have apocrine origins. Hence, there
usually exists a pilosebaceous, eccrine, or apocrine pre-
dominant morphology which allows classification of skin
adnexal tumors into one of these three groups of origin
[1, 2].
As previously mentioned, hidradenocarcinoma is tradi-
tionally regarded as a malignancy of eccrine cutaneous
sweat glands. In this report, we present a case of a patient
with a hidradenocarcinoma with apocrine features. The
dilemma of classifying this lesion and its behavior will be
discussed.
Case Report
A 33-year-old man presented with a 4 month history of an
enlarging left scalp mass. The patient denied any pain or
parasthesias associated with the mass or any history of
trauma to the area. He did note that the mass would
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occasionally bleed. He had no history of significant sun
exposure, alcohol or tobacco use.
Physical examination revealed a 5 9 5 9 4 cm painless
mass at the left posterior scalp (Fig. 1). The mass appeared
to be extremely vascular with normal overlying skin. The
mass did not feel to be fixated to the underlying calvarium.
In addition, multiple enlarged left level V lymph nodes
were palpated.
The mass was evaluated by both computed tomography
(CT) and magnetic resonance (MR). On CT, the mass was
clearly identified and noted not to have an calvarial
involvement. By MR imaging, the mass was relatively
isointense on T1 weighted images, slightly bright on T2
weighted images with flow voids (Fig. 2). On both MR and
CT, the presence of significant left-sided cervical adenop-
athy was evident. A PET scan was also obtained which
showed abnormal uptake at the left posterior scalp and
mid-left lower neck. No distant lesions were identified.
Incisional biopsies were performed and a diagnosis of a
malignant adnexal neoplasm was given. The patient was
presented at our multidisciplinary tumor board and the
recommendation was to perform a wide local excision of
the primary mass and a modified radical neck dissection of
the ipsilateral neck. The decision to give postoperative
adjuvant treatment would be made after final pathology.
The patient underwent wide local excision of the mass
and a left neck dissection of levels I–V. Surgical margins
were achieved. On microscopic exam, the mass was con-
sistent with an infiltrative carcinoma with clear cell
morphology and focal squamous differentiation, with focal
sebaceous differentiation and connection to a hair follicle,
numerous duct-like structures, and myxoid stroma (Figs. 3
and 4). Immunohistochemical staining was grossly positive
for HMW-cytokeratin (Fig. 5) and focally positive for
CEA. CAM 5.2, CK7, CK20, S-100, TTF-1, and CDX2
were all negative. A final diagnosis of apocrine hidrade-
nocarcinoma was made.
Discussion
Although adnexal malignancies comprise \1% of all head
and neck cancers, it is nevertheless important for the head
and neck surgeon to understand the classification and
behavior of these tumors. As mentioned, adnexal tumors
have been classified based on their predominant morphol-
ogy. Traditionally, these tumors were categorized as
having a pilosebaceous, eccrine, or apocrine origin.
However, some investigators have pointed to the exis-
tence of tumors of mixed morphology, such as tumors
exhibiting both apocrine and eccrine differentiation. This
has prompted the suggestion that certain skin adnexal
tumors may arise out of a totipotent stem cell instead [1].
More relevantly, such observations have prompted some to
question the usefulness and accuracy of traditional desig-
nations of cutaneous sweat gland tumors as either of
eccrine or apocrine in origin [2–4]. The traditional asso-
ciation of hidradenocarcinoma with eccrine morphology
compared to our current observation of apocrine hidrade-
nocarcinoma certainly supports this line of thought.
Several other examples help explain the motivation
behind questioning traditional eccrine and apocrine desig-
nations. First is the aforementioned example of the
existence of mixed eccrine/apocrine lesions such as syrin-
gocystadenoma papilliferum and poroma [2]. Second,
many tumors which have been previously classified as
apocrine have been found in areas where apocrine glands
typically do not exist [3]. Third, closer examination of
many lesions traditionally classified as eccrine have
revealed the existence of apocrine and apoeccrine coun-
terparts as well [2]. Given that many past examples of
eccrine or apocrine designation of cutaneous sweat gland
tumors were based on poor or incomplete evidence, Ko and
colleagues undertook a study carefully examining the his-
tological and immunohistochemical characteristics of a
series of six hidradenocarcinomas. Their conclusion was
that all the samples demonstrated histological features
consistent with both eccrine and apocrine differentiation
[3]. Fourth is the observation that that there exists apoec-
crine glands in the axillary region and also glands called
cutaneous mammary-like glands in the anogenital region
that demonstrate features of all three skin appendages.
Because of all these reasons, combined apoeccrine desig-
nation has been proposed for many cutaneous sweat gland
tumors including the hidradenocarcinoma [2, 3].
In addition, many tumors show features suggestive of
folliculosebaceous apocrine unit (FSAU) derivation, with
both follicular and/or sebaceous areas as well as ductal
Fig. 1 After the patient’s scalp has been shaved, the 5 9 5 9 4 cm
mass at the left parietal scalp as seen upon initial presentation
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areas, which are most likely apocrine [4]. Hidradenocar-
cinoma and hidradenoma, its benign counterpart, may be
FSAU derived in some cases.
Nonetheless, many pathologists have continued to
classify cutaneous sweat gland tumors by their predomi-
nant morphology and the designations of eccrine, apocrine,
and FSA remain consistently used. In general, some char-
acteristics of eccrine glands include the following:
excretory coil cells are positive for low molecular weight
keratin, epithelial membrane antigen, and carcinoembry-
onic antigen; the myoepithelial layer may demonstrate
smooth muscle actin, p63, and calponin; cells in the
intraepidermal portion are positive for high molecular
weight keratin and cytokeratin 14. In addition, some cells
are also positive for bcl-2 and estrogen and progesterone
receptors. The clinical implication of this is that hormonal
therapy may potentially be used as part of the treatment of
such eccrine tumors [2].
In contrast, pure apocrine lesions are usually negative
for bcl-2 and estrogen and progesterone receptors, though
its glandular epithelium is often positive for androgen
receptors. Apocrine lesions tend to be found where apo-
crine glands are concentrated, such as the axilla and
anogenital areas, but they can also be found in other areas
such as the umbilicus, eyelid, areola, and external auditory
meatus. Such lesions usually demonstrate abundant eosin-
ophilic cytoplasm and have PAS-positive diastase-resistant
granules and iron pigment. Eccentric, basally located
nuclei and decapitation secretion are also commonly seen.
Its luminal cells are positive for epithelial membrane
antigen and carcinoembryonic antigen, while its secretory
cells are positive for low molecular weight keratin [2].
As mentioned, case reports of hidradenocarcinoma have
predominantly detailed lesions of supposed eccrine mor-
phology. This is perhaps partly due to the possibility that
many supposedly eccrine lesions are truly apocrine,
apoeccrine, or FSAU derived lesions. In addition, hidrad-
enocarcinoma, to begin with, is extremely rare. However,
apocrine differentiation does occur. The histological and
immunohistochemical profile of the hidradenocarcinoma
can span a wide spectrum and may include various markers
typically ascribed to eccrine and apocrine glands as
described above. Reflecting this wide spectrum is the
variety of names that have been used to describe the tumor:
malignant nodular/clear cell hidradenoma, malignant
acrospiroma, malignant clear cell acrospiroma, and clear
cell eccrine carcinoma [2].
Hidradenocarcinoma was first described in 1954 by
Keasby and Hadley as a clear cell eccrine carcinoma.
Reflecting its rarity, hidradenocarcinomas have been
Fig. 2 Axial T1 (a) and coronal
T2 (b) MR images of the left
parietal scalp mass
Fig. 3 Histologic examination showed an infiltrative-appearing,
dermal neoplasm composed of anastomosing cords of eosinophilic
to clear-staining tumor cells with areas of necrosis. High power
examination showed cytologic atypia with enlarged nucleoli and
easily identifiable mitoses (inset)
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described in the literature fewer than 60 times since then
[5]. It usually presents on the face or limbs as an ulcerated
reddish nodule in elderly patients [6]. The tumor is most
distinctly characterized by its frequent clear cell mor-
phology. It is a multinodular solid malignant neoplasm that
demonstrates ductal structures and intracytoplasmic tubular
vacuoles along with areas of invasion and may show tumor
necrosis. It most often arise de novo but may also arise
out of its benign counterpart (hidradenoma). Both cyto-
nuclear atypia and increased mitotic activity, in addition to
infiltrative borders, vascular and neural invasion, and
lymph node metastases, may help distinguish it from
Fig. 4 a The tumor showed
evidence of ductal
differentiation with numerous
patent ductal lumina (arrows).
b In addition, areas of follicular
differentiation were also
apparent, as the tumor showed
attachment to several follicular-
cystic structures
Fig. 5 The tumor cells were
diffusely positive for high
molecular weight cytokeratin
(a), and focally positive in the
ductal areas for CEA (b)
Head and Neck Pathol (2009) 3:42–46 45
hidradenoma. Macroscopically, compared to its benign
counterpart, hidradenocarcinoma appears to be larger, less
well demarcated, and more asymmetrical [2, 5, 7].
The differential diagnosis for hidradenocarcinoma pri-
marily includes tumors exhibiting malignant characteristics
with clear cell cytology. These include clear cell eccrine
carcinoma and porocarcinoma, sebaceous carcinoma,
tricholemmal carcinoma, clear cell squamous cell carci-
noma, balloon cell melanoma, and clear cell basal cell
carcinoma [5, 8]. Clear cell carcinomas metastatic to the
skin such as metastatic renal cell clear cell carcinoma
should also be considered [5].
Another adnexal malignancy with apocrine features that
must also be considered is apocrine carcinoma. Primary
cutaneous apocrine carcinoma is a rare tumor with infre-
quent reports in the literature. This lesion, like
hidradenocarcinoma, has a very high rate of regional lymph
node metastases and recurrence. Despite these aggressive
features, apocrine carcinoma is thought to have a good
prognosis since it is infrequently fatal [9].
In contrast, the prognosis for hidradenocarcinoma is
considered to be poor. Even with aggressive surgical
management, the rate of local recurrence has been seen to
be anywhere from 10 to 50% [10, 11]. Regional lymph
nodes are a common route of metastases; indeed, in more
than 60% of patients, metastases have been reported within
the first 2 years. Hematogenous metastases to periesopha-
geal, peribronchial, periaortic, retroperitoneal lymph
nodes, bones, vertebrae, ribs, pelvis, lung space, viscera,
and pleura have been reported as well. In general, the
prognosis for 5 year disease-free survival is \30% [7].
In addition to aggressive surgical excision (which is
generally considered to be the standard treatment), some
have recommended removal of regional lymph nodes due
to the high rates of metastases [11]. However, partly due to
the rare nature of the tumor, the role of lymph node
dissection, sentinel lymph node biopsy, and lymphade-
nectomy on survival remains to be determined, as does the
role of adjuvant chemotherapy. Reports on the effective-
ness of radiotherapy have been conflicting, with some
reports showing radiotherapy to be an effective treatment
and other reports demonstrating radio-resistance [5, 7].
The use of Mohs micrographic surgery has also been
reported. Wildemore et al reported three patients with
hidradenocarcinoma of the lower back, groin, and scalp
treated with Mohs surgery to be free of any evidence of
metastatic disease at 44, 41, and 30 months respectively
[10].
In summary, apocrine hidradenocarcinoma can be
viewed as an aggressive malignant lesion of cutaneous
sweat glands on a spectrum that involves both eccrine and
apoeccrine or FSAU derived lesions. These lesions, in most
cases, may be derived from a pluripotent precursor cell
with the capacity for multiple lines of adnexal differenti-
ation, which could account for the morphologic variability
of these tumors. However, the fact that hidradenocarcino-
mas, regardless of their degree of apocrine or eccrine
differentiation, show a similar aggressive behavior, should
dictate that these lesions be treated in a similar fashion.
Although the data is limited, the treatment of these lesions
should include aggressive surgical excision with regional
lymphadenectomy and adjuvant therapy.
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